Last reviewed · How we verify

NCT05583981

Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery

Completed Last updated 2 March 2023
What this trial tests

trial testing Interview in Breast Carcinoma in 31 participants. Completed in 15 June 2022.

Timeline
1 December 2021
Primary endpoint
15 June 2022
15 June 2022

Quick facts

Lead sponsorOhio State University Comprehensive Cancer Center
StatusCompleted
Study typeOBSERVATIONAL
Enrollment31
Start date1 December 2021
Primary completion15 June 2022
Estimated completion15 June 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Ohio State University Comprehensive Cancer Center

Who can join

18 and older, any sex, with Breast Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study investigates the barriers to implementing breast Synoptic Operative Reports. Information from this study may help researchers identify performance objectives for the breast Synoptic Operative Reports to be adopted, implemented and continued.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Interview

Trials testing the same drug.

Other recruiting trials for Breast Carcinoma

Currently open trials in the same condition.

Other Ohio State University Comprehensive Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05583981.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing